Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.
Identifieur interne : 002507 ( PubMed/Curation ); précédent : 002506; suivant : 002508Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.
Auteurs : Erika Martina [Allemagne] ; Nikolaus Stiefl ; Björn Degel ; Franziska Schulz ; Alexander Breuning ; Markus Schiller ; Radim Vicik ; Knut Baumann ; John Ziebuhr ; Tanja SchirmeisterSource :
- Bioorganic & medicinal chemistry letters [ 0960-894X ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- métabolisme : Cysteine endopeptidases, Protéines virales.
- pharmacologie : Aziridines, Inhibiteurs de protéases, Peptides.
- traitement médicamenteux : Syndrome respiratoire aigu sévère.
- Humains, Sites de fixation, Virus du SRAS.
English descriptors
- KwdEn :
- MESH :
- chemical , metabolism : Cysteine Endopeptidases, Viral Proteins.
- chemical , pharmacology : Aziridines, Peptides, Protease Inhibitors.
- drug effects : SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- Binding Sites, Humans.
Abstract
The coronavirus main protease, M(pro), is considered a major target for drugs suitable to combat coronavirus infections including the severe acute respiratory syndrome (SARS). In this study, comprehensive HPLC- and FRET-substrate-based screenings of various electrophilic compounds were performed to identify potential M(pro) inhibitors. The data revealed that the coronaviral main protease is inhibited by aziridine- and oxirane-2-carboxylates. Among the trans-configured aziridine-2,3-dicarboxylates the Gly-Gly-containing peptide 2c was found to be the most potent inhibitor.
DOI: 10.1016/j.bmcl.2005.09.012
PubMed: 16216498
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002507
Links to Exploration step
pubmed:16216498Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.</title><author><name sortKey="Martina, Erika" sort="Martina, Erika" uniqKey="Martina E" first="Erika" last="Martina">Erika Martina</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Pharmacy and Food Chemistry, University of Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmacy and Food Chemistry, University of Würzburg</wicri:regionArea></affiliation></author><author><name sortKey="Stiefl, Nikolaus" sort="Stiefl, Nikolaus" uniqKey="Stiefl N" first="Nikolaus" last="Stiefl">Nikolaus Stiefl</name></author><author><name sortKey="Degel, Bjorn" sort="Degel, Bjorn" uniqKey="Degel B" first="Björn" last="Degel">Björn Degel</name></author><author><name sortKey="Schulz, Franziska" sort="Schulz, Franziska" uniqKey="Schulz F" first="Franziska" last="Schulz">Franziska Schulz</name></author><author><name sortKey="Breuning, Alexander" sort="Breuning, Alexander" uniqKey="Breuning A" first="Alexander" last="Breuning">Alexander Breuning</name></author><author><name sortKey="Schiller, Markus" sort="Schiller, Markus" uniqKey="Schiller M" first="Markus" last="Schiller">Markus Schiller</name></author><author><name sortKey="Vicik, Radim" sort="Vicik, Radim" uniqKey="Vicik R" first="Radim" last="Vicik">Radim Vicik</name></author><author><name sortKey="Baumann, Knut" sort="Baumann, Knut" uniqKey="Baumann K" first="Knut" last="Baumann">Knut Baumann</name></author><author><name sortKey="Ziebuhr, John" sort="Ziebuhr, John" uniqKey="Ziebuhr J" first="John" last="Ziebuhr">John Ziebuhr</name></author><author><name sortKey="Schirmeister, Tanja" sort="Schirmeister, Tanja" uniqKey="Schirmeister T" first="Tanja" last="Schirmeister">Tanja Schirmeister</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16216498</idno><idno type="pmid">16216498</idno><idno type="doi">10.1016/j.bmcl.2005.09.012</idno><idno type="wicri:Area/PubMed/Corpus">002507</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002507</idno><idno type="wicri:Area/PubMed/Curation">002507</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002507</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.</title><author><name sortKey="Martina, Erika" sort="Martina, Erika" uniqKey="Martina E" first="Erika" last="Martina">Erika Martina</name><affiliation wicri:level="1"><nlm:affiliation>Institute of Pharmacy and Food Chemistry, University of Würzburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Institute of Pharmacy and Food Chemistry, University of Würzburg</wicri:regionArea></affiliation></author><author><name sortKey="Stiefl, Nikolaus" sort="Stiefl, Nikolaus" uniqKey="Stiefl N" first="Nikolaus" last="Stiefl">Nikolaus Stiefl</name></author><author><name sortKey="Degel, Bjorn" sort="Degel, Bjorn" uniqKey="Degel B" first="Björn" last="Degel">Björn Degel</name></author><author><name sortKey="Schulz, Franziska" sort="Schulz, Franziska" uniqKey="Schulz F" first="Franziska" last="Schulz">Franziska Schulz</name></author><author><name sortKey="Breuning, Alexander" sort="Breuning, Alexander" uniqKey="Breuning A" first="Alexander" last="Breuning">Alexander Breuning</name></author><author><name sortKey="Schiller, Markus" sort="Schiller, Markus" uniqKey="Schiller M" first="Markus" last="Schiller">Markus Schiller</name></author><author><name sortKey="Vicik, Radim" sort="Vicik, Radim" uniqKey="Vicik R" first="Radim" last="Vicik">Radim Vicik</name></author><author><name sortKey="Baumann, Knut" sort="Baumann, Knut" uniqKey="Baumann K" first="Knut" last="Baumann">Knut Baumann</name></author><author><name sortKey="Ziebuhr, John" sort="Ziebuhr, John" uniqKey="Ziebuhr J" first="John" last="Ziebuhr">John Ziebuhr</name></author><author><name sortKey="Schirmeister, Tanja" sort="Schirmeister, Tanja" uniqKey="Schirmeister T" first="Tanja" last="Schirmeister">Tanja Schirmeister</name></author></analytic><series><title level="j">Bioorganic & medicinal chemistry letters</title><idno type="ISSN">0960-894X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aziridines (pharmacology)</term><term>Binding Sites</term><term>Cysteine Endopeptidases (metabolism)</term><term>Humans</term><term>Peptides (pharmacology)</term><term>Protease Inhibitors (pharmacology)</term><term>SARS Virus (drug effects)</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Viral Proteins (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aziridines (pharmacologie)</term><term>Cysteine endopeptidases (métabolisme)</term><term>Humains</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Peptides (pharmacologie)</term><term>Protéines virales (métabolisme)</term><term>Sites de fixation</term><term>Syndrome respiratoire aigu sévère (traitement médicamenteux)</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cysteine Endopeptidases</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Aziridines</term><term>Peptides</term><term>Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cysteine endopeptidases</term><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Aziridines</term><term>Inhibiteurs de protéases</term><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Binding Sites</term><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Sites de fixation</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The coronavirus main protease, M(pro), is considered a major target for drugs suitable to combat coronavirus infections including the severe acute respiratory syndrome (SARS). In this study, comprehensive HPLC- and FRET-substrate-based screenings of various electrophilic compounds were performed to identify potential M(pro) inhibitors. The data revealed that the coronaviral main protease is inhibited by aziridine- and oxirane-2-carboxylates. Among the trans-configured aziridine-2,3-dicarboxylates the Gly-Gly-containing peptide 2c was found to be the most potent inhibitor.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16216498</PMID><DateCompleted><Year>2006</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0960-894X</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>24</Issue><PubDate><Year>2005</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Bioorganic & medicinal chemistry letters</Title><ISOAbbreviation>Bioorg. Med. Chem. Lett.</ISOAbbreviation></Journal><ArticleTitle>Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.</ArticleTitle><Pagination><MedlinePgn>5365-9</MedlinePgn></Pagination><Abstract><AbstractText>The coronavirus main protease, M(pro), is considered a major target for drugs suitable to combat coronavirus infections including the severe acute respiratory syndrome (SARS). In this study, comprehensive HPLC- and FRET-substrate-based screenings of various electrophilic compounds were performed to identify potential M(pro) inhibitors. The data revealed that the coronaviral main protease is inhibited by aziridine- and oxirane-2-carboxylates. Among the trans-configured aziridine-2,3-dicarboxylates the Gly-Gly-containing peptide 2c was found to be the most potent inhibitor.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martina</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute of Pharmacy and Food Chemistry, University of Würzburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stiefl</LastName><ForeName>Nikolaus</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Degel</LastName><ForeName>Björn</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Schulz</LastName><ForeName>Franziska</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Breuning</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Schiller</LastName><ForeName>Markus</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Vicik</LastName><ForeName>Radim</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Baumann</LastName><ForeName>Knut</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ziebuhr</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Schirmeister</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>10</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioorg Med Chem Lett</MedlineTA><NlmUniqueID>9107377</NlmUniqueID><ISSNLinking>0960-894X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001388">Aziridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001388" MajorTopicYN="N">Aziridines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>07</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>08</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>09</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>6</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>10</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16216498</ArticleId><ArticleId IdType="pii">S0960-894X(05)01159-5</ArticleId><ArticleId IdType="doi">10.1016/j.bmcl.2005.09.012</ArticleId><ArticleId IdType="pmc">PMC7127417</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur J Med Chem. 2005 Jan;40(1):57-62</Citation><ArticleIdList><ArticleId IdType="pubmed">15642409</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2002 Mar;83(Pt 3):595-599</Citation><ArticleIdList><ArticleId IdType="pubmed">11842254</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chem Biol. 2004 Oct;11(10):1445-53</Citation><ArticleIdList><ArticleId IdType="pubmed">15489171</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Opin Microbiol. 2004 Aug;7(4):412-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15358261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1997 May;71(5):3992-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9094676</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1992 Dec;66(12):7168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">1331517</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>EMBO J. 2002 Jul 1;21(13):3213-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12093723</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem Lett. 2003 Nov 17;13(22):3989-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14592491</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2004 Oct 22;576(3):325-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15498556</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anal Biochem. 2005 Feb 15;337(2):262-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15691506</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Pept Res. 1999 Sep;54(3):242-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10517162</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bioorg Med Chem. 2004 May 15;12(10):2517-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15110833</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Comput Chem. 2005 Apr 15;26(5):484-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15693056</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2000 Apr;81(Pt 4):853-79</Citation><ArticleIdList><ArticleId IdType="pubmed">10725411</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 2004 May 4;43(17):4906-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15109248</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 2005;287:57-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15609509</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Mini Rev Med Chem. 2003 Sep;3(6):585-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12871161</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 2004 Nov 30;43(47):14958-70</Citation><ArticleIdList><ArticleId IdType="pubmed">15554703</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13190-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14585926</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chem Rev. 2002 Dec;102(12):4639-750</Citation><ArticleIdList><ArticleId IdType="pubmed">12475205</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Aug 20;321(2):370-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15358186</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>FEBS Lett. 2004 Sep 10;574(1-3):116-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15358550</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Acta Pharmacol Sin. 2003 Jun;24(6):497-504</Citation><ArticleIdList><ArticleId IdType="pubmed">12791174</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 1997 Jan;78 ( Pt 1):71-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9010287</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2003 Aug 15;308(1):148-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12890493</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 2004 Feb 26;47(5):1079-80</Citation><ArticleIdList><ArticleId IdType="pubmed">14971887</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002507 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002507 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:16216498
|texte= Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:16216498" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |